The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche; Gilead Sciences; Merck (Inst)
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Exelixis (Inst); Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Partner Therapeutics (Inst); QED Therapeutics (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Ipsen
 
Bruno Sangro
Consulting or Advisory Role - Adaptimmune; AstraZeneca; Bayer; Bristol-Myers Squibb; BTG; H3 Biomedicine; Ipsen; Lilly; Merck; Onxeo; Roche/Genentech; Sirtex Medical
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Ipsen; Lilly; Sirtex Medical
Research Funding - Bristol-Myers Squibb (Inst); Onxeo (Inst); Sirtex Medical (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Bristol-Myers Squibb; Sirtex Medical
Other Relationship - Medscape; Target Pharmasolutions
 
William Proctor Harris
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Exelixis; Neo Therma; QED therapeutics; Zymeworks
Research Funding - Agios (Inst); ArQule (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); BTG (Inst); Exelixis (Inst); Halozyme (Inst); MedImmune (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Eisai
 
Masafumi Ikeda
Honoraria - Astellas Pharma; Bayer Yakuhin; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Gilead Sciences; Kaken Pharmaceutical; Lilly Japan; MSD; Mylan; Novartis; Otsuka; SERVIER; Taiho Pharmaceutical; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; Micron; MSD; Novartis; Ono Pharmaceutical; SERVIER; Shire; Teijin Pharma
Research Funding - ASLAN Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Eisai (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst)
 
Takuji Okusaka
Honoraria - Abbvie; AstraZeneca; Bayer; Celgene; Daiichi Sankyo; EA pharma; Eisai; Fujifilm; Lilly; Meiji Seika Kaisha; MSD; Mundipharma; Nippon Shinyaku; Novartis; Ono Pharmaceutical; Pfizer; SERVIER; Shire; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Dainippon Sumitomo Pharma; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Baxter (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Takara Bio
 
Yoon-Koo Kang
Consulting or Advisory Role - ALX Oncology; Amgen; Astellas Pharma; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Macrogenics; Merck Serono; Novartis; Ono Pharmaceutical; Surface Oncology; Taiho Pharmaceutical; Zymeworks
 
Shukui Qin
No Relationships to Disclose
 
Wai Meng David Tai
No Relationships to Disclose
 
Ho Yeong Lim
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Eisai; MSD Oncology
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai
 
Thomas Yau
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology
Consulting or Advisory Role - Bristol-Myers Squibb
 
Wei-Peng Yong
Consulting or Advisory Role - Abbvie/Genentech; Amgen; Bristol-Myers Squibb; Ipsen; Novartis
Speakers' Bureau - Eisai; Lilly; Sanofi/Aventis; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Pfizer
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Genentech/Roche; Lilly
Consulting or Advisory Role - AstraZeneca; Bayer Schering Pharma; BeiGene; Bristol-Myers Squibb; CSR Pharma; Eisai; Genentech/Roche; IQVIA; MSD; Novartis; Ono Pharmaceutical
 
Antonio Gasbarrini
Consulting or Advisory Role - Abbvie; Actial; Alfasigma; Bristol-Myers Squibb; Gilead Sciences; MSD; Sanofi; Takeda
Speakers' Bureau - Abbvie; Actial; Alfasigma; Bristol-Myers Squibb; Gilead Sciences; MSD; Sanofi; Takeda
 
Filippo G. De Braud
Honoraria - Bristol-Myers Squibb; Merck; MSD; Pfizer; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Bristol-Myers Squibb; EMD SERONO; Ignyta; Incyte; Nerviano Medical Sciences; Octimet; Pierre Fabre; Roche; Sanofi; Teofarma
Speakers' Bureau - Menarini
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Roche (Inst); SERVIER (Inst); Tesaro (Inst)
 
Jordi Bruix
Consulting or Advisory Role - Abbvie; Adaptimmune; ArQule; AstraZeneca/MedImmune; Basilea; Bayer; BioAlliance Pharma; Bristol-Myers Squibb; BTG; Eisai; Gilead Sciences; Incyte; Ipsen; Kowa; Lilly; MSD; Nerviano Medical Sciences; Novartis; Quirem Medical; Roche; Sanofi; Sirtex Medical; TERUMO
 
Mitesh J. Borad
Stock and Other Ownership Interests - AVEO; Gilead Sciences; GlaxoSmithKline
Consulting or Advisory Role - Agios (Inst); ArQule (Inst); Celgene (Inst); Fujifilm (Inst); G1 Therapeutics; Halozyme (Inst); Inspyr Therapeutics; Insys Therapeutics (Inst); Novartis (Inst); Pieris Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TD2
Research Funding - Agios (Inst); ARIAD (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Celgene (Inst); Dicerna (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); ImClone Systems (Inst); Incyte (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); miRNA Therapeutics (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Celgene
 
Philip He
Employment - AstraZeneca
 
Alejandra Negro
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Masatoshi Kudo
Honoraria - Bayer; Eisai; MSD
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; MSD; Ono Pharmaceutical
Research Funding - Abbvie (Inst); EA Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Agios; AstraZeneca; Bayer; BeiGene; BiolineRx (I); Bristol-Myers Squibb; Celgene; CytomX Therapeutics (I); Debiopharm Group; Eisai; Exelixis; Flatiron Health; Flatiron Health; Genoscience Pharma; Gilead Sciences; Ipsen; Janssen (I); LAM Therapeutics; Lilly; Loxo (I); Merck Serono; Minapharma; Pfizer (I); QED Therapeutics; RedHill Biopharma; Roche; Sanofi; Silenseed (I); Sillajen; SOBI (I); Targovax (I); twoXAR; Vicus Therapeutics; Yiviva
Research Funding - Acta Biologica (Inst); Agios (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Exelixis (Inst); Genentech (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); MabVax (Inst); Novartis (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Polaris